Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Anxiety patents



      

This page is updated frequently with new Anxiety-related patent applications.




Date/App# patent app List of recent Anxiety-related patents
05/19/16
20160137643 
 1,7-naphthyridine derivatives patent thumbnailnew patent 1,7-naphthyridine derivatives
Personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, parkinson's disease, dementia, alzheimer's disease, cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, selected from alcohol, opiates, methamphetamine, phencyclidine and cocaine.. .

05/19/16
20160137620 
 Phenyl-piperazine derivatives as serotonin reuptake inhibitors patent thumbnailnew patent Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder..

05/12/16
20160130278 
 Glycine transporter inhibitor patent thumbnailGlycine transporter inhibitor
Which are useful in the prevention or treatment of diseases such as schizophrenia, alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.. .

05/12/16
20160129060 
 Composition for the treatment of neurobehavioral disorders patent thumbnailComposition for the treatment of neurobehavioral disorders
The invention relates to a composition for use in the treatment of neurobehavioral disorders, a cannabis plant extract comprising cannabinol preferably with other constituents of this plant for such use and a method for the extraction of plants. The plants or plant parts may for instance be derived from cannabis sativa and/or cannabis indica and/or cannabis ruderalis and/or citrus fruits, and mixtures thereof.
Cannais Science International Holding B.v.


05/05/16
20160121116 
 Methods and devices for treating primary headache patent thumbnailMethods and devices for treating primary headache
Non-invasive electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including sinus symptoms that resemble an immune-mediated response (“sinus” headaches), irrespective of whether those symptoms arise from an allergy that is co-morbid with the headache.
Electrocore, Llc


04/28/16
20160114015 
 Treatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin patent thumbnailTreatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin
Methods are disclosed for treating social anxiety disorder, obsessive compulsive disorder, and/or panic disorder in a subject. The methods include administering a therapeutically effective amount of a neurotoxin to a corrugator supercilli and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilli and/or a procerus muscle in the subject, thereby treating ptsd.

04/21/16
20160106808 
 Treatment of mood and anxiety disorders patent thumbnailTreatment of mood and anxiety disorders
As follows from the background section, above, there is a need in the art for improved methods for the treatment of mood and/or anxiety disorders. The present disclosure provides therapeutic agents and methods for treating mood (e.g., major depressive disorder) and anxiety disorders (e.g., ocd, ptsd).

04/07/16
20160095844 
 Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives patent thumbnailIndolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives
The compounds may be used for the treatment of certain central nervous system disorders which are positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, alzheimer's disease, autism, parkinson's disease, chronic pain, borderline personality disorder, sleep disturbances, chronic fatigue syndrome, stiffness, antiinflammatory effects in arthritis and balance problems.. .

03/03/16
20160058754 
 Nalmefene for treatment of patients with anxiety disorder patent thumbnailNalmefene for treatment of patients with anxiety disorder
The present invention relates to nalmefene for use in the treatment of anxiety disorders. The present invention further relates to nalmefene for use in the treatment of patients with alcohol dependence who have a co-morbid anxiety disorder.
H. Lundbeck A/s


02/18/16
20160046583 
 Isoquinoline derivatives patent thumbnailIsoquinoline derivatives
For the treatment of schizophrenia, obsessive-compulsive personality disorder, depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, parkinson's disease, dementia, alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine or cocaine.. .

02/11/16
20160038559 

Methods and compositions for inhibiting glyoxalase 1 (glo1)


Methods and compositions are provided for treating or preventing a neurological disease or disorder using an inhibitor of glyoxalase 1 (glo1). In some embodiments, the inhibitor is a small molecule.
The University Of Chicago


01/21/16
20160019801 

System and improving presentation skills


A system and method for improving social and presentation skills of persons with a social communication disorder such as autism. Social anxiety or a lack of confidence, the method including: rendering and displaying on a display device a presentation script for an oral presentation to be made by a user; monitoring eye movement of the user during the oral presentation to measure a user's pupil movement and/or a user's gaze direction; displaying an indicia on a separate display screen and/or an upper portion of the display device; periodically displaying within the presentation script a visual prompt to cue the user to look at the indicia; measuring eye movement using eye tracking software and/or an eye tracking device, at occurrence of the visual prompt; and evaluating whether the user made eye contact with the indicia when prompted..
Autismsees Llc


01/21/16
20160016963 

Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-one


The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, parkinson's disease, dementia, alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.. .

01/07/16
20160002623 

Genes expressed in mental illness and mood disorders


The present invention relates to a composition comprising a plurality of cdna molecules for use in methods of detecting changes in expression of genes encoding proteins that are associated with mental illnesses and which are differentially expressed in patients with mental illnesses, such as bipolar i disorder, bipolar ii disorder, unipolar disorder, schizophrenia, attention deficit hyperactive disorders, obsessive compulsive disorders, anxiety disorders or other related mood disorders. The composition and the cdna molecules may be used in their entirety or in part as to diagnose, to stage, to treat, and/or to monitor the treatment of a subject with mental illness..
Psychnostics, Llc


11/26/15
20150336904 

Rufinamide and derivatives and their use in modulating the gating process of human voltage-gated sodium channels


The present invention provides compounds of formula i which are capable of inhibition of the activation of hnav1.1 or hnav1.6 sodium channels in neurons. Pharmaceutical compositions comprising these compounds are also provided.
The Johns Hopkins University


11/12/15
20150322058 

Oxytocin receptor agonists for the treatment of cns diseases


Or a pharmaceutically acceptable acid addition salt, or a racemic mixture or its corresponding enantiomer and/or optical isomers thereof, for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrome.. .

10/29/15
20150309050 

Diagnostic and therapeutic methods and products related to anxiety disorders


The present invention relates to diagnostic, prognostic and therapeutic methods related to anxiety, as well as related products. In particular examples the anxiety is post-traumatic stress disorder..

10/29/15
20150306136 

Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders


The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (ptsd) in subjects, e.g., human subjects, by administering a xenon and/or argon containing composition. Treatments can also employ psychotherapy in combination with administration of xenon and/or argon, alone or in combination with additional psychotherapeutic medications to treat the anxiety disorder and reduce a symptom of the anxiety disorder in the subject..
The Mclean Hospital Corporation


10/22/15
20150297688 

Botulinum toxin and the treatment of primary disorders of mood and affect


A method of treating depression includes identifying a subject with a pain syndrome for increased responsiveness to the treatment of pain associated with the pain syndrome with botulinum toxin and locally administering a botulinum toxin subcutaneously to a face of the subject, thereby treating said pain. Identification of the pain is made prior to administering botulinum toxin for the treatment of said pain.
Botulinum Toxin Research Associates, Inc.


10/08/15
20150284434 

Peptides as oxytocin agonists


It has been found that the present compounds are oxytocin receptor agonists for the treatment of autism, stress, including post traumatic stress disorder, anxiety, including anxiety disorders and depression, schizophrenia, psychiatric disorders and memory loss, alcohol withdrawal, drug addiction and for the treatment of prader-willi syndrom.. .

10/01/15
20150274670 

Heterocyclic compounds for the treatment of neurological and psychological disorders


Lactam compounds of formula i and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.. .
Alkermes Pharma Ireland Limited


09/24/15
20150265836 

Electrical and magnetic stimulators used to treat migraine/sinus headache, rhinitis, sinusitis, rhinosinusitis, and comorbid disorders


Transcutaneous electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including nasal or paranasal sinus symptoms that resemble an immune-mediated response (“sinus” headaches).
Electrocore, Llc


09/24/15
20150265830 

Electrical and magnetic stimulators used to treat migraine/sinus headache, rhinitis, sinusitis, rhinosinusitis, and comorbid disorders


Transcutaneous electrical nerve stimulation devices and magnetic stimulation devices are disclosed, along with methods of treating medical disorders using energy that is delivered noninvasively by such devices. The disorders comprise migraine and other primary headaches such as cluster headaches, including nasal or paranasal sinus symptoms that resemble an immune-mediated response (“sinus” headaches).
Electrocore, Llc


09/17/15
20150259414 

Anti-acth antibodies and use thereof


The present invention is directed to antibodies and fragments thereof having binding specificity for acth. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the vh, vl and/or cdr polypeptides described herein, and the polynucleotides encoding them.
Alder Biopharmaceuticals, Inc.


09/17/15
20150259341 

Imidazopyridine derivatives


The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, parkinson's disease, dementia, alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.. .

09/17/15
20150259334 

Benzisoxazoles


The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, parkinson's disease, dementia, alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.. .

09/17/15
20150258128 

Gabaergic receptor subtype selective ligands and their uses


Described herein are α3 or α2 or α2/α3 gabaergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 gabaergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases..
Uwm Research Foundation, Inc.


09/10/15
20150252044 

Substituted 1,6-naphthyridines


For the treatment of schizophrenia, obsessive-compulsive personality disorder, depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, parkinson's disease, dementia, alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs selected from alcohol, opiates, methamphetamine, phencyclidine or cocaine.. .

09/03/15
20150246922 

Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one


The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, parkinson's disease, dementia, alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.. .

08/27/15
20150239832 

Analogs and prodrugs of loop diuretics, including bumetanide, furosemide and piretanide; compositions and methods of use


Novel analogs and prodrugs of the loop diuretics bumetanide, furosemide and piretanide are described. Pharmaceutical compositions containing loop diuretic analogs and prodrugs are also described.
Neuro Pro Therapeutics, Inc.


08/20/15
20150231330 

Method of treating depression, mood disorders and anxiety disorders using neuromodulation


The present application involves a method and a system for using electrical stimulation and/or chemical stimulation to treat depression. More particularly, the method comprises surgically implanting an electrical stimulation lead and/or catheter that is in communication with a predetermined site which is coupled to a signal generator and/or infusion pump that release either an electrical signal and/or a pharmaceutical resulting in stimulation of the predetermined site thereby treating the mood and/or anxiety..
Advanced Neuromodulation Systems, Inc.


08/20/15
20150231138 

Sulfur-containing bicyclic compound


A sulfur-containing bicyclic compound of the present invention has a pam action of gabab. A composition containing the sulfur-containing bicyclic compound.
Astellas Pharma Inc.


08/13/15
20150224157 

Process for the preparation of herbal extract of cassia tora leaves for treating anxiety disorders


The present invention relates to novel use of the extracts of cassia tora plant species. The present invention particularly relates to novel use of the extracts of cassia tora leaves, which show antianxiety activity.
Council Of Scientific And Industrial Research


08/06/15
20150218131 

Pyrazole carboxamide compounds and uses thereof


The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (adhd), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as parkinson's disease, neurodegenerative disorders such as alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.. .

07/23/15
20150203472 

Benzimidazoles as cns active agents


The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, parkinson's disease, dementia, alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.. .

07/09/15
20150191458 

Triazole carboxamides and uses thereof


The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (adhd), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as parkinson's disease, neurodegenerative disorders such as alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.. .

07/02/15
20150183768 

Heteroaromatic methyl cyclic amine derivative


A heteroaromatic methyl cyclic amine derivative represented by formula (ia) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, alzheimer's disease, parkinson's disease, huntington's disease, eating disorder, cephalalgia, hemicrania, pain, digestive diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases and hypertension, on the basis of an orexin (ox) receptor antagonist activity.. .
Taisho Pharmaceutical Co., Ltd.


06/25/15
20150175573 

Heteroaromatic compounds and their use as dopamine d1 ligands


And pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, impulsivity, compulsive gambling, overeating, autism spectrum disorder, mci, age-related cognitive decline, dementia, rls, parkinson's disease, huntington's chorea, anxiety, depression, mdd, trd, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, sle, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.. .

06/18/15
20150167093 

Method for identifying increased risk of anxiety disorders


The present invention is for methods for identifying a human having an increased risk for anxiety disorders. The method involves genotyping the human for a specific brain-derived neurotrophic factor (bdnf) single nucleotide polymorphism (snp), and/or administering a fear conditioning procedure while measuring fear, and administering an extinction procedure while measuring fear.
Cornell University


06/18/15
20150166534 

Novel anxiolytic compounds


Which may possess useful therapeutic activity in a range of central nervous system disorders, and in particular, anxiety disorders.. .

06/18/15
20150166523 

Branched chain alkyl heteroaromatic ring derivative


A branched chain alkyl heteroaromatic ring derivative represented by formula (ia) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, alzheimer's disease, parkinson's disease, huntington's disease, eating disorder, cephalalgia, hemicrania, pain, digestive diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases and hypertension, on the basis of the orexin (ox) receptor antagonist activity.. .
Taisho Pharmaceutical Co., Ltd.


06/04/15
20150152057 

Compositions and methods for the treatment of neurologic diseases


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of neurologic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

06/04/15
20150152042 

Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity


Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, attention deficit hyperactivity disorder, fibromyalgia, irritable bowel syndrome, and/or premature ejaculation are described.. .
Auspex Pharmaceuticals, Inc.


05/21/15
20150141669 

Prodrug of fluorine-containing amino acid


Provided are a fluorine-containing amino acid prodrug represented by general formula (i) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof. More specifically, provided is a prodrug that increases the in vivo exposure and enhances the oral absorbability and other mucosal absorbability of a parent compound that acts on group 2 metabotropic glutamate receptors as an agent for the treatment or prevention of diseases in which group 2 metabotropic glutamate receptors are said to be involved, such as: schizophrenia, anxiety disorder and its related diseases, depression, bipolar disorder, epilepsy, developmental disorders, sleep disorders, and other neuropsychiatric diseases; and drug dependence, cognitive disorders, alzheimer's disease, huntington's chorea, parkinson's disease, movement disorders associated with muscular rigidity, cerebral ischemia, cerebral insufficiency, spinal cord disorders, cephalopathy, and other neurological diseases..
Taisho Pharmaceutical Co., Ltd.


05/21/15
20150141500 

Compositions and methods for the treatment of neurological diseases


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Anxiety for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Anxiety with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.2498

5462

0 - 1 - 103